MGF

MGF (Mechano Growth Factor) is a splice variant of the IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents) that is transiently expressed in skeletal muscle, cardiac muscle, bone, and other mechanosensitive tissues in response to mechanical loading or tissue damage. The IGF-1 gene on chromosome 12q23.2 undergoes alternative splicing of exons 4-6 to produce multiple isoforms with the same mature IGF-1 protein but different C-terminal E-peptide extensions. MGF's unique 24-amino-acid C-terminal E-peptide, encoded by a reading frame shift in exon 5, is the bioactive feature that distinguishes MGF from the systemic IGF-1Ea isoform. The E-peptide activates muscle satellite cells and initiates the repair response. Despite extensive preclinical evidence, no human clinical trials of MGF or PEG-MGF have been performed. The compound is sold as a research chemical and used off-label in bodybuilding and sports-recovery contexts. WADA prohibits all IGF-1 isoforms and related substances under Section S2.

Discovery and the Two-Phase Model

MGF was first characterized by Geoffrey Goldspink and Shi Yu Yang at University College London in the mid-1990s. Building on basic muscle biology research, Goldspink's group identified a distinct IGF-1 mRNA transcript in mechanically loaded rabbit and rat muscle that differed from the previously known systemic IGF-1Ea isoform. The new variant was named Mechano Growth Factor to reflect its responsiveness to mechanical loading.

The seminal paper came in 2002: Yang and Goldspink in FEBS Letters02918-6) demonstrated that the unique E-peptide of MGF (24 amino acids) could activate quiescent satellite cells and promote myoblast proliferation independently of the mature IGF-1 domain. The mature IGF-1 peptide, common to all IGF-1 isoforms, primarily drove myoblast differentiation and fusion rather than initial activation.

This established the two-phase model of IGF-1 splice variant function in muscle repair:

1. Phase 1 (early, hours after damage): Mechanical stress or muscle damage triggers rapid MGF mRNA expression. The MGF E-peptide activates quiescent satellite cells, stimulating their entry into the cell cycle and proliferation.
2. Phase 2 (later, days after damage): Splicing shifts toward IGF-1Ea expression. Mature IGF-1 drives myoblast differentiation, fusion, and protein synthesis through IGF-1R/PI3K/AKT/mTOR signaling, leading to muscle fiber hypertrophy.

The temporal separation is a clean example of how alternative splicing can produce different biological effects from a single gene.

Preclinical Hypertrophy Evidence

The most-cited preclinical evidence for MGF's hypertrophic effect comes from rodent studies in which intramuscular MGF injection produced substantial muscle fiber hypertrophy. The Goldspink group reported that intramuscular injection of MGF into rat tibialis anterior muscle produced approximately a 25 percent increase in mean muscle fiber cross-sectional area within two weeks, a striking magnitude for a peptide intervention.

Other preclinical findings:

• MGF mRNA upregulation within hours of mechanical loading or damage
• Sustained satellite cell expansion with continued MGF exposure
• Synergy with subsequent IGF-1Ea-driven hypertrophy
• MGF expression in cardiac muscle after ischemic injury
• MGF expression in bone, particularly in response to mechanical loading
• MGF expression in the growth plate (Philippou and colleagues, 2013)
• MGF expression in endometrium with abnormal expression in endometriosis

These findings established MGF as a plausible therapeutic candidate for muscle-wasting conditions including sarcopenia, cachexia, and disuse atrophy.

The Pharmacokinetic Problem

The principal obstacle to clinical development of MGF is its extremely short serum half-life. The unmodified 24-amino-acid E-peptide is degraded within approximately 5 to 7 minutes by serum proteases. This pharmacokinetic profile makes systemic administration impractical for any sustained therapeutic effect.

Two approaches have addressed this:

1. PEGylation: conjugation to polyethylene glycol (PEG-MGF) extends the half-life to several hours by reducing renal clearance and proteolytic degradation
2. Local administration: intramuscular injection near the target muscle can produce local concentrations sufficient for effect before the peptide is cleared, exploiting the original biology of MGF as a paracrine muscle factor

Both approaches have been explored only in preclinical research-chemical contexts. The PEG-MGF approach is the one used in commercial peptide markets. See the separate PEG-MGF article for the PEGylated form's specific profile.

Clinical Development: Essentially Absent

Unlike most growth factors discussed in the peptide literature, MGF has not undergone clinical development. No Investigational New Drug (IND) program at the FDA, no major pharmaceutical company sponsorship, and no published human clinical trials exist for either MGF or PEG-MGF as of 2026.

The reasons for the absent clinical development pipeline likely include:

• The cancer-pathway theoretical concern with IGF-1-related signaling
• The pharmacokinetic challenge of the very short half-life
• The competitive field of muscle-wasting therapies (myostatin antagonists, SARMs, GH secretagogues, GLP-1 RA-related compounds)
• Patent rights complications around splice variants
• The absence of a clear unmet clinical need where MGF's unique mechanism would provide differentiated benefit

The result is that MGF biology is well-characterized in preclinical research but the translation to human therapeutic use remains unrealized.

Research-Chemical Market and Off-Label Use

Synthetic MGF (the 24-amino-acid E-peptide) and PEG-MGF are sold by research-chemical vendors and compounding pharmacies. Off-label use is concentrated in bodybuilding, athletic performance, and sports-recovery communities, where MGF is positioned as a "local IGF-1" that targets specific muscle groups when injected nearby. Common community claims:

• Faster muscle recovery after intense training
• Increased local muscle hypertrophy in injected sites
• Improved tissue repair after muscle injury
• Synergy with IGF-1 LR3 or growth hormone secretagogues
• "Site enhancement" effects for specific muscle groups

These claims are based on the rodent preclinical data and anecdotal user reports. No controlled human trials support them.

Regulatory Status

• FDA: Not approved. No IND program. Research chemical status.
• EMA: Not approved
• WADA: Prohibited under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) at all times in all sports
• Compounding: MGF and PEG-MGF have appeared on FDA Section 503A bulk substance evaluations. Their status under 503A bulk substance regulations is contested. FDA has issued enforcement actions against compounders selling these substances.

MGF's mechanism centers on satellite cell activation through the unique E-peptide, distinct from the IGF-1 receptor signaling that drives the systemic IGF-1Ea isoform.

The Splice Variant Biology

The IGF-1 gene contains 6 exons. Alternative splicing produces different mRNA transcripts:

• IGF-1Ea: predominant systemic isoform, produced by liver under GH stimulation, mediates circulating IGF-1 effects
• IGF-1Eb: rodent isoform similar in role to human IGF-1Ec
• IGF-1Ec (MGF): human muscle-derived isoform, expressed in response to mechanical loading

The differences between the isoforms are in the C-terminal E-peptide. The mature IGF-1 protein produced from the central exons is identical across the isoforms. The functional differences therefore arise from the E-peptide cleavage products.

E-Peptide Receptor Pharmacology

The full IGF-1Ec protein is presumably cleaved post-translationally to release both the mature IGF-1 domain (which can signal through the IGF-1 receptor like any other IGF-1) and the unique E-peptide (which appears to signal through a separate, incompletely characterized receptor system).

The 24-amino-acid MGF E-peptide is the bioactive region used in research-chemical products. The receptor through which it activates satellite cells is not the IGF-1 receptor (IGF-1R) and remains incompletely characterized. Some research suggests a distinct membrane receptor or GPCR. The signaling does not appear to require PI3K/AKT/mTOR (the IGF-1R pathway) but may involve other proliferative cascades.

Satellite Cell Activation

Satellite cells are the quiescent muscle stem cells that reside between the sarcolemma and basal lamina of muscle fibers. Upon activation, they enter the cell cycle, proliferate to expand the myogenic precursor cell pool, and then differentiate to fuse with existing muscle fibers (hypertrophy) or to form new muscle fibers (hyperplasia, more limited in adult mammals).

The MGF E-peptide activates satellite cells via:

• Promoting cell-cycle entry from quiescence
• Increasing myogenic regulatory factor expression (MyoD, Myf5)
• Stimulating proliferation
• Delaying differentiation (allowing the precursor pool to expand before fusion occurs)

This delaying-of-differentiation effect is functionally important because it allows the satellite cell pool to expand before commitment to fusion. The subsequent shift to IGF-1Ea expression then drives the differentiation phase.

Mechano-Transduction Pathway

The upstream signal that triggers MGF expression in response to mechanical loading involves the mechano-transduction pathway: mechanical force at the sarcomere is sensed by costameric proteins (vinculin, talin, dystrophin complex), transduced through integrin-linked signaling, and converted into alternative splicing of the IGF-1 pre-mRNA. The exact splicing factors involved (potentially including splicing regulators responsive to mechanical signals) remain under investigation.

Cardiac and Other Tissue Effects

MGF is also expressed in cardiac muscle, bone, growth plate, endometrium, and other mechanosensitive tissues. In cardiac muscle, MGF expression is upregulated after ischemic injury and may contribute to repair through cardiomyocyte survival and progenitor activation, though the cardiac role is less well characterized than the skeletal muscle role.

Effects in preclinical (rodent and cell culture) models:

• Satellite cell activation and proliferation (cell culture, in vivo)
• Approximately 25 percent increase in muscle fiber cross-sectional area in rat tibialis anterior after intramuscular MGF (Goldspink group)
• Accelerated recovery from mechanical and electrical muscle damage
• Faster muscle regeneration after toxin-induced injury
• Cardiomyocyte protection in ischemia/reperfusion models
• Improved cardiac function recovery after myocardial infarction (rodent)
• Improved bone formation in response to mechanical loading
• Modulation of growth plate chondrocyte proliferation
• Neuroprotective effects in some CNS injury models

Effects in human research: not characterized in controlled clinical trials

Effects reported in off-label bodybuilding and sports-recovery contexts (uncontrolled, anecdotal):

• Local muscle hypertrophy at injection sites
• Faster recovery between training sessions
• Reduced soreness and faster repair after muscle injury
• Subjective improvement when stacked with IGF-1 LR3 or growth hormone secretagogues
• Variable response: some users report dramatic effects, others minimal

Honest evidence framing: MGF has a well-developed preclinical evidence base for satellite cell activation and muscle hypertrophy. The translation to human therapeutic effect has not been validated in any controlled clinical trial. The off-label community claims are based on preclinical data and uncontrolled user reports. The compound is not appropriate for therapeutic use outside of investigational contexts, and the WADA prohibition makes it inappropriate for any competitive athlete.

Important note: there is no FDA-approved dosing protocol for MGF. The doses described below are from research-chemical community protocols and rodent preclinical studies, not from controlled human trials.

Off-label community protocols (unmodified synthetic MGF):

• Local intramuscular dose: 100 to 200 mcg injected directly into or near the target muscle, post-workout
• Frequency: 2 to 3 times per week per muscle group
• Cycle: 4 to 8 weeks, sometimes longer
• Total daily dose: 200 to 500 mcg if multiple sites injected

PEG-MGF protocols (see separate PEG-MGF article):

• 200 to 500 mcg subcutaneously 2 to 3 times per week
• Systemic effect intended rather than purely local
• Half-life extension allows less frequent dosing

Timing considerations:

• Post-workout is the common timing in off-label use, based on the rationale that mechanical stress from training already primes the muscle for MGF signaling
• Some users dose pre-workout or both pre- and post-workout
• No controlled comparison of timing strategies exists

Routes:

• Intramuscular near target muscle: traditional off-label approach exploiting the local paracrine biology
• Subcutaneous: more practical for PEG-MGF systemic dosing
• Intravenous: not used in off-label contexts due to peptide nature

Reconstitution and storage:

• Lyophilized peptide reconstituted with bacteriostatic water or sodium chloride
• Refrigeration after reconstitution
• Stability of reconstituted peptide: typically 2 to 4 weeks at 2-8°C
• PEG-MGF has somewhat better stability than unmodified MGF
• Vendor quality and identity verification varies substantially

Special populations:

• Pregnancy and breastfeeding: not studied. Avoid
• Pediatric: not approved or studied. Avoid
• Active or recent cancer: theoretical contraindication due to IGF-1-related signaling
• Athletes subject to anti-doping testing: WADA-prohibited at all times
• Renal/hepatic impairment: no data

Reported effects in off-label use (uncontrolled, anecdotal):

• Mild injection-site reactions (redness, swelling, transient pain)
• Mild fatigue or lethargy in some users
• Headache (occasional)
• Mild flushing
• Hypoglycemia (rare, related to potential IGF-1 receptor cross-reactivity at high doses)
• Joint pain (occasional, similar to high-dose IGF-1 or GH use)

Theoretical and uncharacterized concerns:

• Cancer risk: this is the principal theoretical concern with any IGF-1-pathway-engaging compound. IGF-1 signaling is implicated in proliferation and survival of many tumor types (breast cancer, colorectal cancer, prostate cancer, others). MGF promotes satellite cell proliferation and may activate similar growth-promoting pathways in transformed cells. The relationship between exogenous MGF administration and cancer risk in humans is uncharacterized. Active or recent cancer is a meaningful theoretical contraindication.
• Acromegaly-like effects: chronic high-dose use could theoretically produce acromegaly-like features (jaw enlargement, organ enlargement, soft-tissue thickening) if MGF cross-engages IGF-1R signaling at high doses, though this is less of a concern than with full-length recombinant IGF-1
• Insulin sensitivity: theoretical effect on glucose metabolism through IGF-1R cross-reactivity
• Cardiac effects: theoretical concern with chronic activation of cardiac MGF signaling, particularly in athletes already exposed to athletic cardiac remodeling
• Immunogenicity: anti-MGF antibodies can develop with repeated administration. Functional implications uncharacterized
• Quality and contamination: research-chemical market quality varies substantially. Endotoxin contamination, identity issues, and bacterial contamination of reconstituted product are practical risks

Pregnancy and breastfeeding: avoid. No data.

Pediatric: avoid outside research contexts. No data.

Athletes: WADA-prohibited under Section S2 at all times in all sports. Detection methods for IGF-1 isoforms exist. Use carries substantial doping-violation risk.

Quality concerns specific to MGF research-chemical market:

• Identity verification often absent (the 24-amino-acid E-peptide is short enough that purity by mass spec is technically feasible but rarely documented)
• Endotoxin contamination possible with non-pharmaceutical-grade products
• Some vendors sell mislabeled products (PEG-MGF sold as MGF or vice versa)
• Reconstitution practices in home environments increase contamination risk

MGF sits at the intersection of growth factor biology and bodybuilding research-chemical use. Its closest comparators:

• PEG-MGF: PEGylated form of MGF with extended half-life. The practical commercial form for systemic dosing. Same E-peptide biology, different pharmacokinetics.
• IGF-1 LR3: Long R3 IGF-1, a modified full-length IGF-1 with extended half-life. Different mechanism (full IGF-1 protein, IGF-1R signaling) but used in similar bodybuilding contexts as a complementary or alternative growth factor.
• IGF-1 DES: truncated IGF-1 variant with enhanced local potency. Different mechanism, different pharmacokinetics.
• HGH Fragment 176-191: not a growth factor in the IGF-1 sense. Targets adipose tissue specifically. Different mechanism but used in similar performance contexts.
• Growth hormone secretagogues (CJC-1295, Ipamorelin, Tesamorelin): upstream of MGF biology, increasing endogenous GH and then IGF-1 and (presumably) MGF expression. Different regulatory status (Tesamorelin is FDA-approved for HIV lipodystrophy).

Common stacks circulating in bodybuilding communities:

• MGF + IGF-1 LR3: rationale of combining local satellite cell activation (MGF) with systemic anabolic IGF-1 effect (LR3). Common but not validated in any controlled trial.
• MGF + Growth Hormone Secretagogues (CJC-1295 + Ipamorelin): rationale of combining endogenous GH pulse increase with MGF E-peptide local injection. Popular "bulking stack" in research-chemical bodybuilding.
• MGF + BPC-157 / TB-500: combined satellite cell activation and tissue repair. Used particularly for injury recovery contexts.
• MGF + Testosterone (for users on TRT): rationale of combining anabolic AR signaling with local muscle growth. Risk profile is more substantial. Testosterone has its own monitoring requirements.

Combinations to avoid or use with caution:

• Active or recent cancer: theoretical contraindication due to IGF-1-pathway cancer concerns
• Pregnancy and breastfeeding: avoid all growth factor compounds
• Athletes subject to WADA testing: MGF use is a doping violation
• Active acromegaly or pituitary tumors: avoid additional growth-factor signaling
• Insulin-dependent diabetes: monitor glucose carefully with any IGF-1-related compound

The most actionable framing of MGF in 2026: this is one of the best-characterized muscle growth factors at the preclinical level, with three decades of research from the Goldspink group at UCL and others. The molecular biology (splice variant, E-peptide, satellite cell activation, two-phase model) is well-established. The translation to human therapeutic use is essentially absent: no human clinical trials, no FDA approval, no major pharmaceutical sponsorship. The off-label use in bodybuilding is based on preclinical data and anecdotal reports, not controlled human evidence. The cancer-pathway theoretical concerns are not negligible and warrant caution in any individual with a personal or family cancer history. Athletes should not use MGF under any circumstances due to WADA prohibition. For most individuals interested in muscle recovery and tissue repair, BPC-157, TB-500, or even simple optimization of training, sleep, and protein intake provide better-validated risk/benefit profiles than MGF.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.